{"organizations": [], "uuid": "681f8ff866f636d61dd4f0bed1dabf7ca83608ab", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kalytera-announces-issuance-of-pat/brief-kalytera-announces-issuance-of-patent-covering-the-use-of-cbd-for-the-treatment-of-severe-and-refractory-graft-versus-host-disease-idUSFWN1RW0IK", "country": "US", "domain_rank": 408, "title": "BRIEF-Kalytera Announces Issuance Of Patent Covering The Use Of CBD For The Treatment Of Severe And Refractory Graft Versus Host Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.687, "site_type": "news", "published": "2018-04-19T19:38:00.000+03:00", "replies_count": 0, "uuid": "681f8ff866f636d61dd4f0bed1dabf7ca83608ab"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kalytera-announces-issuance-of-pat/brief-kalytera-announces-issuance-of-patent-covering-the-use-of-cbd-for-the-treatment-of-severe-and-refractory-graft-versus-host-disease-idUSFWN1RW0IK", "ord_in_thread": 0, "title": "BRIEF-Kalytera Announces Issuance Of Patent Covering The Use Of CBD For The Treatment Of Severe And Refractory Graft Versus Host Disease", "locations": [], "entities": {"persons": [{"name": "kalytera", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "kalytera therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Kalytera Therapeutics Inc:\n* KALYTERA ANNOUNCES ISSUANCE OF PATENT COVERING THE USE OF CBD FOR THE TREATMENT OF SEVERE AND REFRACTORY GRAFT VERSUS HOST DISEASE\n* KALYTERA THERAPEUTICS INC - KALYTERA ALSO EXPECTS TO INITIATE AN ADDITIONAL PHASE 2 CLINICAL STUDY IN TREATMENT OF GVHD LATER THIS YEAR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T19:38:00.000+03:00", "crawled": "2018-04-20T12:13:30.005+03:00", "highlightTitle": ""}